EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study

Eemeli Puhakka iD, Hany Ahmed iD, Retu Haikonen iD, Sophie Leclercq iD, Kati Hanhineva iD, Luca Maccioni iD, Camille Amadieu iD, Marko Lehtonen iD, Ville Männistö iD, Jaana Rysä iD, Peter Stärkel iD, Olli Kärkkäinen iD

Liver International · 2025

DOI: 10.1111/liv.70128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Eemeli Puhakka und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Eastern Finland, Kuopio, Finland. Hauptthemen laut MEDLINE: Liver Diseases, Alcoholic, Metabolome, Fatty Liver, Alcoholic, Liver Cirrhosis, Alcoholic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jane ja Aatos Erkon Säätiö, Fonds De La Recherche Scientifique - FNRS, Alkoholitutkimussäätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Alcohol‐related liver disease (ALD) is a major cause of mortality and disability‐adjusted life years. It is not fully understood why a small proportion of patients develop progressive forms of ALD (e.g., fibrosis and cirrhosis). Differences in the metabolic processes could be behind the individual progression of ALD. Our aim was to examine differences in serum metabolome between patients with nonprogressive ALD and patients with an early form of progressive ALD.

Methods

The study had three study groups: progressive ALD (alcohol‐related steatohepatitis or early‐stage fibrosis, n = 50), nonprogressive ALD (simple steatosis, n = 50) and healthy controls ( n = 32). Both ALD groups took part in a voluntary alcohol rehabilitation programme. A nontargeted metabolomics analysis and targeted analysis of short‐chain fatty acids were done to the serum samples taken on the day of admission.

Results

We found 111 significantly ( p < 0.0005) altered identified metabolites between the study groups. Our main finding was that levels of glycine‐conjugated bile acids (Cohen's d = 0.90–0.91), glutamic acid ( d = 1.01), 7‐methylguanine ( d = 0.77) and several phosphatidylcholines ( d = 0.61–0.85) were elevated in the progressive ALD group in comparison to the nonprogressive ALD group. Glycine‐conjugated bile acids, glutamic acid and 7‐methylguanine also positively correlated with increased levels of aspartate aminotransferase, alanine aminotransferase, gamma‐glutamyl transferase, cell death biomarker M65 and liver stiffness.

Conclusions

Our results indicate that the enterohepatic cycle of glycine‐conjugated bile acids, as well as lipid and energy metabolism, is altered in early forms of progressive ALD. These metabolic processes could be a target for preventing the progression of ALD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Diseases, AlcoholicMetabolomeFatty Liver, AlcoholicLiver Cirrhosis, AlcoholicHumansMaleFemaleMetabolomicsMiddle AgedCross-Sectional StudiesDisease ProgressionAdultCase-Control StudiesBiomarkersBile Acids and SaltsGlutamic Acid

Stichwörter der Autor:innen

bile acidsfibrosisglutamatic acidmetabolomicssteatosis

Substanzen

BiomarkersBile Acids and SaltsGlutamic Acid

Autor:innen und Institutionen

  • School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • Food Sciences Unit, Department of Life Technologies, University of Turku, Turku, Finland.
  • Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
  • Laboratory of Nutritional Psychiatry, Institute of Neuroscience, UCLouvain, Université Catholique de Louvain, Brussels, Belgium.
  • National Institute of Alcohol Abuse and Alcoholism, Bethesda, Maryland, USA.
  • Université de Bordeaux, NutriNeuro, Bordeaux, France.

ORCID-Profile: Eemeli Puhakka, Hany Ahmed, Retu Haikonen, Sophie Leclercq, Kati Hanhineva, Luca Maccioni, Camille Amadieu, Marko Lehtonen, Ville Männistö, Jaana Rysä, Peter Stärkel, Olli Kärkkäinen

Förderung

  • Jane ja Aatos Erkon Säätiö
  • Fonds De La Recherche Scientifique - FNRS
  • Alkoholitutkimussäätiö
  • Academy of Finland
  • Research Council of Finland

Zitieren

APA

Puhakka, E., Ahmed, H., Haikonen, R., Leclercq, S., Hanhineva, K., Maccioni, L., Amadieu, C., Lehtonen, M., Männistö, V., Rysä, J., Stärkel, P., & Kärkkäinen, O. (2025). Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study. Liver International. https://doi.org/10.1111/liv.70128

Vancouver

Puhakka E, Ahmed H, Haikonen R, Leclercq S, Hanhineva K, Maccioni L, et al. Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study. Liver International. 2025. doi:10.1111/liv.70128

BibTeX
@article{Puhakka2025,
  author = {Puhakka, Eemeli and Ahmed, Hany and Haikonen, Retu and Leclercq, Sophie and Hanhineva, Kati and Maccioni, Luca and Amadieu, Camille and Lehtonen, Marko and Männistö, Ville and Rysä, Jaana and Stärkel, Peter and Kärkkäinen, Olli},
  title = {Serum Metabolite Profile in Progressive Versus Nonprogressive Alcohol‐Related Liver Disease: A Cross‐Sectional Metabolomics Study},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70128}
}
Kostenlos starten →